翻訳と辞書 |
NeuVax
NeuVax, developed by Galena Biopharma, Inc., is a peptide-based vaccine aimed at preventing or delaying the recurrence of breast cancer in cancer survivors who achieve remission after standard of care treatment (e.g., surgery, radiation, chemotherapy). It consists of the E75 synthetic peptide initially isolated from HER2/neu proto-oncogene (being HER2/neu p366-379〔) combined with the immune adjuvant, granulocyte macrophage colony stimulating factor (rhGM-CSF from yeast). NeuVax works by harnessing the patient’s own immune system to seek out and attack any residual cancer cells that express HER2/neu, a protein associated with tumors in breast, ovarian, pancreatic, colon, bladder and prostate cancers. ==Clinical trials== NeuVax has been tested as adjuvant treatment in nearly 200 breast cancer patients over a total of 5 years, and has shown to be safe and effective in Phase 2 trials. As a result, two additional NeuVax trials registered or underway are: (1) a 700 patient Phase 3 trial for FDA approval - not yet recruiting and (2) a 300 patient Phase 2 trial studying the combination of NeuVax and Herceptin® (trastuzumab).
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「NeuVax」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|